Qelbree® (viloxazine extended-release capsules) is commercially available in
“This partnership represents the continued execution of our strategy of expanding our presence in CNS and entering in one of the most important segments still presenting relevant unmet medical needs,” said
Supernus was able to identify in Knight the right commercial experience and capabilities to get Qelbree® approved and successfully launch it in
About ADHD8
ADHD is a neurodevelopmental disorder that affects both children and adults. The estimated prevalence of ADHD is 5-9% in children and 3-5% in adults. The disorder is characterized by symptoms of inattention, hyperactivity, and impulsivity that can significantly impact an individual's ability to function in daily life. Although patients’ symptoms of ADHD can change over time, they will generally require continued monitoring and treatment over their lifetime. Current pharmacotherapies for ADHD include amphetamine or methylphenidate-based psychostimulants as well as long-acting non-psychostimulant options. However, not all patients respond to existing therapies. As a result, there remains a significant medical need for additional treatment options for patients with ADHD.
About
Forward-Looking Statements for Knight
This document contains forward-looking statements for
CONTACT INFORMATION FOR KNIGHT:
Investor Contact: | ||
Arvind Utchanah | ||
President & Chief Executive Officer | Chief Financial Officer | |
T: 514.484.4483 | T. +598.2626.2344 | |
F: 514.481.4116 | ||
Email: IR@knighttx.com | Email: IR@knighttx.com | |
Website: www.knighttx.com | Website: www.knighttx.com |
References:
- Nasser A et al. (2020). A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children. Clinical Therapeutics, 42(8), 1452-1466. DOI: https://doi.org/10.1016/j.clinthera.2020.05.021
- Nasser A et al. (2021). Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial. Clinical Therapeutics, 43(4), 684-700. DOI: https://doi.org/10.1016/j.clinthera.2021.01.027
- Nasser A et al. (2021). A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Journal of Clinical Psychopharmacology , 41(4), 370-380. DOI: 10.1097/JCP.0000000000001404 - Nasser A et al. (2022). A Phase III, Randomized, Double‑Blind, Placebo‑Controlled Trial Assessing the Efcacy and Safety of Viloxazine Extended‑Release Capsules in Adults with Attention‑Defcit/Hyperactivity Disorder. CNS Drugs, 36(8), 897-915. DOI: https://doi.org/10.1007/s40263-022-00938-w
- US
National Library of Medicine . (2021,March 8 - ). Open-label study of SPN-812 administered with psychostimulants in children and adolescents with ADHD (ADHD). Identifier NCT04786990. https://clinicaltrials.gov/study/NCT04786990 - Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms. (2023,
September 10 ). Retrieved from https://ir.supernus.com/node/13856/pdf - US
National Library of Medicine . (2021,March 4 - ). Evaluation of SPN-812 (viloxazine extended-release capsule) in preschool-age children with ADHD. Identifier NCT04781140. https://clinicaltrials.gov/study/NCT04781140 - CADDRA -
Canadian ADHD Resource Alliance . (2020). Canadian ADHD Practice Guidelines, 4.1 Edition. https://adhdlearn.caddra.ca/wp-content/uploads/2022/08/Canadian-ADHD-Practice-Guidelines-4.1-January-6-2021.pdf - Presented during Supernus Pharmaceuticals R&D Day;
October 18, 2023
Source:
2023 GlobeNewswire, Inc., source